MAPK3 and Myocardial fibrosis: Zhang et al.’s [219] research uncovered that hUCMSCs, administered in a rat model with myosin-induced dilated cardiomyopathy, could reduce myocardial fibrosis and dysfunction by controlling the expression of TNF-α, ERK1/2, and TGF-β1.